Not an actual patient.
“I struggle
with my inhalers.”
-Robert
Not an actual patient.
“I have impaired
inspiratory flow.”
-Maria
Not an actual patient.
“Susan is experiencing
cognitive decline.”
-Susan’s husband and caregiver
Not an actual patient.
“I am transitioning from
hospital to home care.”
-Ken
Not an actual patient.
“I’m using my short-acting
bronchodilator, but my
symptoms are still getting worse.” -Diane
Selected responses from a 127-question, quantitative, web-based, descriptive, cross-sectional survey of 499 patients with COPD in the United States. Survey participants were aged 55 to 74 years, predominantly former smokers, and were randomly chosen from a panel of individuals with self-identified COPD.
This is not a guarantee of coverage. Site of Care will determine coverage. Check with your patient’s insurance provider for coverage rules and restrictions. In certain limited instances, YUPELRI may be covered through a patient’s Medicare Part D pharmacy benefit.
Among COPD patients in the United States:
~45%
have a nebulizer at home†
Based on the estimated prevalence of COPD in the US, several million patients use nebulizers on a regular basis4
YUPELRI is contraindicated in patients with hypersensitivity to revefenacin or any component of this product.
YUPELRI should not be initiated in patients during acutely deteriorating or potentially life-threatening episodes of COPD, or for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.
As with other inhaled medicines, YUPELRI can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with YUPELRI, it should be treated immediately with an inhaled, short-acting bronchodilator. YUPELRI should be discontinued immediately and alternative therapy should be instituted.
YUPELRI should be used with caution in patients with narrow-angle glaucoma. Patients should be instructed to immediately consult their healthcare provider if they develop any signs and symptoms of acute narrow-angle glaucoma, including eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema.
Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct patients to contact a healthcare provider immediately if symptoms occur.
Immediate hypersensitivity reactions may occur after administration of YUPELRI. If a reaction occurs, YUPELRI should be stopped at once and alternative treatments considered.
The most common adverse reactions occurring in clinical trials at an incidence greater than or equal to 2% in the YUPELRI group, and higher than placebo, included cough, nasopharyngitis, upper respiratory infection, headache and back pain.
Coadministration of anticholinergic medicines or OATP1B1 and OATP1B3 inhibitors with YUPELRI is not recommended.
YUPELRI is not recommended in patients with any degree of hepatic impairment.
For additional information, please contact us at 1-800-395-3376.
For additional information, please contact us at 1-800-395-3376.
Over half of COPD patients 45+ years are likely to have coexisting arthritis. 12
“I try to use my inhalers every day like my doctor told me to, but it’s hard to use the inhaler properly. It feels like my symptoms are getting worse.” -Robert
44% of COPD patients self-reported having arthritis. Arthritis or other manual dexterity issues may prevent patients from using inhaler devices properly. Other conditions to be aware of which may limit somebody’s physical ability to use an inhaler include poor coordination, neuromuscular conditions, etc.3,*
Approximately 19% of patients with advanced COPD and ≥60 years of age have impaired inspiratory effort. 13
“I use my maintenance inhalers every day, but I’m still out of breath when I walk. So I’ve been using my rescue medication a lot, which worries me.”-Maria
Inspiratory flow is one of many factors to consider when choosing a delivery device.14
As many as one-third of COPD patients were classified as having either borderline or impaired cognitive functioning. 15,16,17†
“Making sure Susan takes her medicine properly can be a challenge—I wish she could use one type of device where she doesn’t need to coordinate her breath.” -Susan’s husband and caregiver
Cognitive impairments in COPD patients are a common barrier to correct inhaler device administration. It is important to consider the role of the caregiver in the assessment of cognitive decline.3,8,15,*
Only 6% of patients with severe COPD used their inhaler therapy regularly and with correct technique a majority of the time in the month following hospital discharge. 15,*
“I keep ending up back in the hospital and don’t feel in control of my COPD. I lack confidence going home without a nebulizer.”-Ken
It is critical for patients to be assessed for medication and device technique before leaving the hospital.8,16
Many COPD patients are undertreated, and over half do not receive the GOLD recommended maintenance medications. 17,18
“I like taking my COPD medication through a nebulizer, but I am now taking my medicine more frequently, at 4 to 6 times a day. It's tough to do the things I used to do.” -Diane
Patients experiencing a worsening of symptoms on their current therapy may need to be reassessed.14
